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Abstract
It has been suggested that, at least in some forms of cancer, a sub-population of slow-cycling, therapy-
resistant cancer stem cells exists that has the ability to reconstitute the tumor in its entirety. If true, this
modelimpliesthatconventionaltherapiesbasedontargetinghighlycyclingcellswithinthetumorwillleave
the slow-cycling stem cell population intact, giving them the opportunity to reinitiate the tumor at a later
date. This review discusses the evidence for this model and the likely implications for cancer treatment.
Relapse is a sword of Damocles hanging over cancer
patients. The removal of the tumor and destruction of its
remains do not preclude the potential propagation of the
tumorlocallyoratdistance,sometimesevenyearslater,by
a few resilient left-over cells. Cancer stem cells have been
equated with this sub-population of therapy-resistant
cells. The cancer stem cell model posits that a small popu-
lation of cells within tumors has the ability to perpetuate
the tumor in its entirety by giving rise to all its cells. By
attributing the “stem cell” label to these cells, the model
projects that these cells have appropriated somatic stem
cell characteristics, that is cancer stem cells that are mostly
dormant or slow-cycling, and are able to regenerate the
entire tumor from which they arise. If true, this model
implies that conventional therapies based on targeting
fast-cyclingcellswithinthetumorwillleavethe(quiescent
or low-cycling) stem cell population intact, giving them
the opportunity to reinitiate the tumor at a later date.
While the cancer stem cell model has given a ray of hope
to patients by reinvigorating cancer research and pointing
to new directions for eradicating these life-threatening
diseases, it has also stirred much confusion and debate.
Cancer stem cells: hype or reality?
The decades-old concept of cancer stem cells was awa-
kened from dormancy by John Dick and his collea-
gues in the 1990s [1-3]. By establishing an in vivo assay
using immunocompromised mice whereby one could
quantify the number of human blood stem cells in
transplanted animals, these investigators identified a
small sub-population of human leukemic cells with a
self-renewing capacity that could regenerate leukemia in
mice. These cells, named leukemia stem cells or leukemia-
initiating cells, shared surface markers with normal blood
stem cells. The observations led the investigators to
conclude that blood stem cells are the target of leukemic
transformation.Basedonthesefindings,theyproposedthat
the leukemic clone (like normal blood cells) is organized
as a hierarchy, leukemia starting in most immature cells
that generate differentiated cells with more restricted
functions. A few years later, using various surface markers,
several groups identified cells with similar characteristics
in several solid tumors, including breast, colon and brain
[4-6], that they calledcancer stem cells.
Despitethesefindings,theconceptofcancerstemcellsand
its relevance to the improvement of cancer therapy and
survival of cancer patients has been highly debated [7,8].
Thekeyquestionremainsastowhetherinterpretingcancer
in the light of cancer stem cell model has an advantage for
patients and whether it will increase the chances of curing
cancer once for all? The answer is not clear and scientists
do not agree. After all, tumors are composed of various
chaoticcellsthatmaynotderivefromasinglecell.Tumors
may be generated from multiple cancer stem cell clones.
Cells that resist treatment may not have any particular
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the exception to the rule, or happen to be the ones
protected by their microenvironment. It has also been
proposed that only some but not all cancers follow the
cancer stem cell model [8].
What is a stem cell?
The concept of stem cells itself might provide some
answers as to why there is disagreement in the scientific
community regarding the value of the cancer stem cell
model. The existence of stem cells and their therapeutic
use was first demonstrated in blood, making blood stem
cells the leading model for stem cell research in other
tissues. Likewise it is with blood that the cancer stem cell
model is revived.
Stem cells are defined by two fundamental properties.
They self-renew, in that every time they divide they give
rise to a cell with an identical stem cell program. And they
are multipotent, in that they have the capacity to generate
all the cells in the tissue they arise from. Stem cells are rare
in most adult tissues, and in fact only a few stem cells are
sufficient to maintain the entire tissue during a lifetime.
Stem cells are mostly dormant, have a low metabolic rate,
low growth factor requirement and live a long life. They
rarely enter the cell cycle but when they do, for instance in
response to cellular loss or damage, they exhibit a trem-
endous potential to regenerate the entire tissue. These
properties insure that these cells stay out of harm’sw a y
and protect them from accumulating mutations that may
occur during cell divisions. They also have an arsenal of
defense mechanisms against chemical and toxic insults
and a strong response system against DNA damage as
compared with their progeny [9,10]. In addition, stem
cells live in a defined environment called a stem cell niche
with which they interact and which has a significant
impact on their fate.
Are all tumor cells equal?
Attheheartofthe cancerstemcellconceptliesthe concept
of tumor heterogeneity. Tumors are composed of various
cell types, some with tumor-initiating potential, others
fast-proliferating or post-mitotic, differentiated and
devoid of tumor-regeneration capacity [11]. Tumorigenic
cells are genetically unstable, harbor various mutations
and are at different stages of development. The cancer
stem cell model argues that a few hidden cells within the
tumor have stem cell-like properties with higher tumori-
genic potential; these cells are able to give rise to all the
cells within tumors, resistant to therapy and responsible
for recurrence of the disease. Cancer stem cells may be
recognized by surface markers and prospectively isolated,
assayed for their tumorigenic function and quantified,
and ultimately targeted for therapy. Regardless of the cell
of origin, cancer follows the stem cell hierarchy, cancer
stemcells areresponsible for disease progression, undergo
epigenetic modifications to give rise to cells with non-
tumorigenic potential (differentiated cells with more
restricted functions) that fill the bulk of the tumor. The
premise is that only cancerstemcellscause the tumor and,
while other tumor cells may cause symptoms resulting
from the bulk of the tumor, only ablation of the cancer
stem cells will ultimately eradicate the tumor and prevent
its return.
Does cancer start in tissue specific stem cells?
The term “cancer stem cell” has been the subject of much
confusion. Oncogenic transformation is the result of
accumulation of several genetic hits that ultimately alter
cellgrowthanddifferentiation.Theterm“cancerstemcell”
suggests that cancer arises from oncogenic transformation
of stem cells. Given that stem cells are around for a long
time and potentially undergo many divisions in response
to demands, they are indeed promising candidates for
accumulating a sufficient number of events required for
oncogenic transformation. Moreover, the oncogenic pro-
cess could be more efficient in stem cells as it may borrow
from these cells their intrinsic machinery in the regulation
ofquiescence and resistance toinsults(sothe oncoprotein
does not have to create such mechanisms; mechanisms
insuring self-renewal of cancer cells are already in place).
Certainly, in the case of chronic myeloid leukemia, the
initial event is in a stem cell. However, there are a number
of studies published that show that cancer stem cells can
be generated by oncogenic transformation of stem cell
progeny [12-14]. The type of oncogene may also play a
role indeterminingwhetherornotstemcellsarethetarget
of oncogenic transformation [12].
To make matters worse, “cancer stem cell”,a n d“tumor-
initiating cell” (or “leukemia-initiating cell” when it
applies) have been used interchangeably, generating
another source of confusion.
The quality of the assay
Another complication is that the definition of cancer stem
cells is intertwined with assays that identify these cells.
Indeed, the power of the cancer stem cell model is to a
large extent limited by the sensitivity of the methodology
that is used for measuring the frequency of these cells.
The“cancerstemcell”labelevokestheideathatthesecells,
likeadultstemcells,arerare.Quantificationofcancerstem
cells, as with normal human stem cells, relies heavily on
using xenotransplantation models in which human cells
are isolated based on their surface markers and injected
into immunocompromised mice in which they regenerate
the original tumor. This approach is based on several
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be separated from neighboring normal cells by a given set
of surface markers. Since tumors are highly heterogeneous
and genomically unstable, proteins expressed on their
surface are unlikely to provide a signature of cancer stem
cells that is specific to a given tissue or cancer. Indeed, it
has been shown in recent studies that some of the most
well known surface markers do not necessarily differenti-
ate between tumorigenic and non-tumorigenic cells.
The second assumption is that, once cancer stem cells are
injected into mice, they home in on the right tissue where
they regenerate the tumor. This presumes that human
tumor cells have the proper combinations of proteins to
interact with host mouse vessels and tissues. The human
cells also have to find the mouse environment hospitable
for survival, growth and expansion. It has therefore been
suggested that only highly tumorigenic cells would meet
these stringent requirements to be detected as cancer stem
cells. Also, the degree to which the mice are immuno-
compromised would also impact the detection of cancer
stem cells, using this assay.
Overall, the quality of the assay used is critical in
identifying cancer stem cells and it is possible that current
results may largely underestimate the true frequency of
these cells. This very point was raised by Sean Morrison
and colleagues in the case of melanomas. These investi-
gators showed in two consecutive studies that, at least in
melanomas,thefrequencyoftumorigeniccellsisveryhigh
to the point that distinguishing cancer stem cells from the
bulk of the tumor may not matter [15,16]. In addition,
they showed that, regardless of the stage of the disease,
the cells expressing markers that were previously recog-
nized as cancer stem cell-specific can be regenerated from
cells categorized as non-tumorigenic [16]. These studies
also excluded the possibility that the high frequency with
which cancer stem cells are detected in certain malig-
nancies is just an indication of the gravity of the disease as
had been suggested previously [17].
It is conceivable, however, that not all cancers follow the
cancer stem cell model. And, after all, even cells that are
scored as cancer stem cells in assays conducted in mice may
not be the ones that are therapy-resistant or the ones that
reinitiate the tumor, i.e. relapse or metastasize in humans.
Are cancer stem cells dormant?
If the therapy-resistant cells are stem cells, they are likely
to be, as many somatic stem cells are, mostly dormant.
The nature of the current assays for measurements of
cancer stem cells precludes the identification of dormant
stem cells, since cancer stem cells are identified by their
ability to proliferate and generate tumors in the host.
Consequently, direct evidence for quiescence of cancer
stem cells has been limited. However, in the case of breast
cancer, it is possible to identify tumor cells with the gene
signatureofnormalstemcells[18].Inagreementwiththis,
other studies showed that a nuclear factor, Foxo3a,
required for the regulation of normal blood stem cell
quiescence [19,20], was found to be essential for main-
tenance of both mouse and human leukemic stem cells
[21,22]. Foxo3 with tumor suppressor properties is critical
forkeepingbloodstemcellsquiescentandparadoxicallyis
also required for maintaining the leukemic stem cell pool
as if the mechanisms that protect quiescence are shared
between normal and cancer stem cells.
How does the concept of cancer stem cells
affect therapy?
If cancer stem cells are rare quiescent cells that are
responsible for disease progression, then these cells
should be targeted along with highly proliferating cells
that compose the bulk of the tumor. What is not clear is
whether the resistant cells in a cancer are cancer stem
cells? Do the non-responding patients have tumors with
more cancer stem cells? And what is the impact of current
treatments like targeting highly proliferating cells on
quiescent cancer stem cells? Is targeting cancer stem cells
alone sufficient for shrinking the tumor? Since the cancer
stem cell model is highly relevant for recurrence of the
cancer, a treatment based on targeting cancer stem cells
may be more effective in preventing future relapses but
this will need to be assessed in much longer term studies
than those reported to date.
The cancer stem cell concept has stimulated lots of
interest, engaged many scientists and injected fresh
enthusiasm into cancer research. The key challenge is to
figure out how to use this model in improving the lives
of cancer patients and for that to happen, many
fundamental questions need yet to be addressed.
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